Logo image of AURA

AURA BIOSCIENCES INC (AURA) Stock Fundamental Analysis

NASDAQ:AURA - Nasdaq - US05153U1079 - Common Stock - Currency: USD

7.51  -0.12 (-1.57%)

After market: 7.51 0 (0%)

Fundamental Rating

3

Taking everything into account, AURA scores 3 out of 10 in our fundamental rating. AURA was compared to 572 industry peers in the Biotechnology industry. While AURA has a great health rating, there are worries on its profitability. AURA is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

AURA had negative earnings in the past year.
In the past year AURA has reported a negative cash flow from operations.
In the past 5 years AURA always reported negative net income.
In the past 5 years AURA always reported negative operating cash flow.
AURA Yearly Net Income VS EBIT VS OCF VS FCFAURA Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2019 2020 2021 2022 2023 -20M -40M -60M -80M

1.2 Ratios

The Return On Assets of AURA (-40.53%) is comparable to the rest of the industry.
The Return On Equity of AURA (-47.64%) is better than 67.14% of its industry peers.
Industry RankSector Rank
ROA -40.53%
ROE -47.64%
ROIC N/A
ROA(3y)-28.36%
ROA(5y)-60.58%
ROE(3y)-31.4%
ROE(5y)-69.53%
ROIC(3y)N/A
ROIC(5y)N/A
AURA Yearly ROA, ROE, ROICAURA Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2019 2020 2021 2022 2023 -50 -100 -150

1.3 Margins

The Profit Margin and Operating Margin and Gross Margin are not available for AURA so they could not be analyzed.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
AURA Yearly Profit, Operating, Gross MarginsAURA Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2019 2020 2021 2022 2023

More info and screens

8

2. Health

2.1 Basic Checks

Compared to 1 year ago, AURA has more shares outstanding
There is no outstanding debt for AURA. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
AURA Yearly Shares OutstandingAURA Yearly Shares OutstandingYearly Shares Outstanding 2019 2020 2021 2022 2023 10M 20M 30M 40M
AURA Yearly Total Debt VS Total AssetsAURA Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2019 2020 2021 2022 2023 50M 100M 150M 200M 250M

2.2 Solvency

AURA has an Altman-Z score of 4.57. This indicates that AURA is financially healthy and has little risk of bankruptcy at the moment.
AURA has a better Altman-Z score (4.57) than 79.22% of its industry peers.
AURA has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z 4.57
ROIC/WACCN/A
WACCN/A
AURA Yearly LT Debt VS Equity VS FCFAURA Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2019 2020 2021 2022 2023 0 50M -50M 100M 150M 200M

2.3 Liquidity

A Current Ratio of 12.47 indicates that AURA has no problem at all paying its short term obligations.
Looking at the Current ratio, with a value of 12.47, AURA belongs to the top of the industry, outperforming 84.55% of the companies in the same industry.
AURA has a Quick Ratio of 12.47. This indicates that AURA is financially healthy and has no problem in meeting its short term obligations.
AURA's Quick ratio of 12.47 is amongst the best of the industry. AURA outperforms 84.72% of its industry peers.
Industry RankSector Rank
Current Ratio 12.47
Quick Ratio 12.47
AURA Yearly Current Assets VS Current LiabilitesAURA Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2019 2020 2021 2022 2023 50M 100M 150M 200M

More info and screens

0

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 9.14% over the past year.
EPS 1Y (TTM)9.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

AURA is expected to show a decrease in Earnings Per Share. In the coming years, the EPS will decrease by -1.85% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y13.69%
EPS Next 2Y-2.84%
EPS Next 3Y-1.85%
EPS Next 5YN/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
AURA Yearly Revenue VS EstimatesAURA Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 500M 1B
AURA Yearly EPS VS EstimatesAURA Yearly EPS VS EstimatesYearly EPS VS Estimates 2019 2020 2021 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 -1 -2 -3 -4

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for AURA. In the last year negative earnings were reported.
Besides the negative Price/Earnings Ratio, also the Forward Price/Earnings Ratio is negative for AURA. No positive earnings are expected for the next year.
Industry RankSector Rank
PE N/A
Fwd PE N/A
AURA Price Earnings VS Forward Price EarningsAURA Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60 80

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
AURA Per share dataAURA EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 1 -1 2 -2 3

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y-2.84%
EPS Next 3Y-1.85%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for AURA!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

AURA BIOSCIENCES INC

NASDAQ:AURA (2/21/2025, 8:02:16 PM)

After market: 7.51 0 (0%)

7.51

-0.12 (-1.57%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)11-12 2024-11-12/amc
Earnings (Next)03-12 2025-03-12/amc
Inst Owners82.83%
Inst Owner Change7%
Ins Owners3.14%
Ins Owner Change29.73%
Market Cap375.12M
Analysts83.08
Price Target22.27 (196.54%)
Short Float %2.51%
Short Ratio7.68
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)8.61%
Min EPS beat(2)6.54%
Max EPS beat(2)10.68%
EPS beat(4)3
Avg EPS beat(4)0.84%
Min EPS beat(4)-33.19%
Max EPS beat(4)19.34%
EPS beat(8)6
Avg EPS beat(8)3.78%
EPS beat(12)8
Avg EPS beat(12)-41.31%
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.65%
PT rev (3m)-0.76%
EPS NQ rev (1m)-0.41%
EPS NQ rev (3m)12.52%
EPS NY rev (1m)0%
EPS NY rev (3m)2.71%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 2.15
P/tB 2.15
EV/EBITDA N/A
EPS(TTM)-1.79
EYN/A
EPS(NY)-2.09
Fwd EYN/A
FCF(TTM)-1.49
FCFYN/A
OCF(TTM)-1.47
OCFYN/A
SpS0
BVpS3.5
TBVpS3.5
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -40.53%
ROE -47.64%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-28.36%
ROA(5y)-60.58%
ROE(3y)-31.4%
ROE(5y)-69.53%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 101.27%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 12.47
Quick Ratio 12.47
Altman-Z 4.57
F-Score4
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)134.58%
Cap/Depr(5y)186.36%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)9.14%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%12.5%
EPS Next Y13.69%
EPS Next 2Y-2.84%
EPS Next 3Y-1.85%
EPS Next 5YN/A
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-19.62%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-48.31%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-50.45%
OCF growth 3YN/A
OCF growth 5YN/A